BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

...sarcoma. Eisai Co. Ltd., Bausch Health Companies Inc. and Minophagen Pharmaceutical Co. Ltd. market Targretin bexarotene...
BioCentury | Jan 27, 2017
Clinical News

Adcetris: Additional Ph III ALCANZA data

...1.6%, p=0.0046) and Skindex-29 symptom domain questionnaire score (p<0.0001) vs. investigator’s choice of methotrexate or bexarotene...
...patients who achieved an objective response lasting ≥4 months vs. investigator’s choice of methotrexate or bexarotene...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Cancer

...causing the metabolic and cutaneous side effects of Targretin bexarotene. Chemical synthesis and testing of Targretin...
...dependent/ SREBP -dependent transcription ratio - a marker of Targretin -induced hypertriglyceridemia - compared with Targretin...
...Co. Ltd. , Minophagen Pharmaceutical Co. Ltd. , and Valeant Pharmaceuticals International Inc. market Targretin bexarotene...
BioCentury | Aug 8, 2016
Clinical News

Adcetris brentuximab vedotin: Phase III data

...patients who achieved an objective response lasting >=4 months vs. investigator’s choice of methotrexate or bexarotene...
BioCentury | Feb 25, 2016
Strategy

Changing the channel

...Medicine. Landreth's study used a mouse model of AD, and showed the RXR agonist Targretin bexarotene...
...the Alzheimer Research Laboratory at Case Western. The Amgen group treated wild-type Sprague-Dawley rats with Targretin...
..."the wrong formulation." In the 2012 study, his group used the clinically approved formulation of Targretin...
BioCentury | Sep 14, 2015
Clinical News

Adcetris brentuximab vedotin: Completed Phase III enrollment

...comparing 1.8 mg/kg IV Adcetris once every 21 days vs. physician’s choice of methotrexate or bexarotene...
BioCentury | Aug 17, 2015
Company News

Mylan sales and marketing update

...Mylan launched bexarotene 75 mg capsules in the U.S. to treat cutaneous manifestations of cutaneous t-cell...
...are refractory to at least one prior systemic therapy. Bexarotene is a generic version of Targretin...
...the product. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Laval, Quebec) has exclusive U.S. rights to Targretin...
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: Retinoid X receptor (RXR)

...AD) In vitro and mouse studies suggest combining docosahexaenoic acid (DHA) and the RXR agonist bexarotene...
...AD. In primary mouse glial cells and a transgenic mouse model of AD, DHA and bexarotene...
...Co. Ltd. , Minophagen Pharmaceutical Co. Ltd. , and Valeant Pharmaceuticals International Inc. market Targretin bexarotene...
BioCentury | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

...In a mouse model of oral carcinogenesis, an RARG agonist plus the RXR agonist Targretin bexarotene...
...steps could include evaluating the combination strategy in additional cancer models. Eisai Co. Ltd. markets Targretin...
BioCentury | May 30, 2013
Targets & Mechanisms

Doubts about Targretin in AD

...by Case Western Reserve University School of Medicine researchers that suggested the cancer drug Targretin bexarotene...
...are expected to report findings from a Phase II trial of bexarotene to treat AD. Targretin...
...study. In each case, the teams examined the effects of Targretin or generic formulations of bexarotene...
Items per page:
1 - 10 of 156